(Q44603186)

4 December 2017

title

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial (English)

1 reference

4 December 2017

main subject

metastatic breast cancer

1 reference

Martin Pecherstorfer

1

1 reference

4 December 2017

Saul Rivkin

2

1 reference

4 December 2017

Jean-Jacques Body

3

1 reference

4 December 2017

Ingo Diel

4

1 reference

4 December 2017

Bengt Bergström

5

1 reference

4 December 2017

publication date

1 January 2006

1 reference

Clinical Drug Investigation

4 December 2017

published in

1 reference

4 December 2017

volume

26

1 reference

4 December 2017

issue

6

1 reference

4 December 2017

page(s)

315-322

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

4 December 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00044011-200626060-00002

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

21 January 2018

1 reference

12 December 2020

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

1 reference

12 December 2020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

1 reference

12 December 2020

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

1 reference

12 December 2020

Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

1 reference

12 December 2020

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

1 reference

12 December 2020

Bisphosphonates in the treatment of bone metastases

1 reference

12 December 2020

Toxic acute tubular necrosis following treatment with zoledronate (Zometa).

1 reference

12 December 2020

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

Renal Failure with the Use of Zoledronic Acid

1 reference

12 December 2020

Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.

1 reference

12 December 2020

10.2165/00044011-200626060-00002

Identifiers

DOI

1 reference

release_yamsols5czh3zp2ofmrodedhmi

4 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yamsols5czh3zp2ofmrodedhmi

24 November 2022

mapped directly with Wikidata item

1 reference